Nath Bio-Genes (India) Limited (BOM:537291)
India · Delayed Price · Currency is INR 175.55
+4.15 (2.42%)
At close: May 29, 2026
Nath Bio-Genes (India) Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 416.3 | 386 | 396.19 | 350.11 | -673.85 |
Depreciation & Amortization | 39.64 | 37.83 | 32.61 | 30.12 | 30.84 |
Other Amortization | - | 0.33 | - | - | - |
Loss (Gain) From Sale of Assets | -0.02 | 10.35 | -0.01 | 0.01 | -0.04 |
Provision & Write-off of Bad Debts | 39.08 | 16.52 | 2.4 | 1.17 | 4.5 |
Other Operating Activities | 70.97 | 74.32 | 83.8 | 100.38 | 998.3 |
Change in Accounts Receivable | -4.21 | 37.56 | 27.65 | -118.83 | 210.23 |
Change in Inventory | -1,125 | -1,077 | -224.63 | 124.96 | 59.57 |
Change in Accounts Payable | 516.37 | 361.87 | 155.61 | -150.46 | 199.92 |
Change in Other Net Operating Assets | -78.54 | 328.11 | 272.32 | 46.2 | -658.99 |
Operating Cash Flow | -125.73 | 175.81 | 745.94 | 383.67 | 170.48 |
Operating Cash Flow Growth | - | -76.43% | 94.42% | 125.05% | 1431.83% |
Capital Expenditures | -30.05 | -79.2 | -267.76 | -28.81 | -210.04 |
Sale of Property, Plant & Equipment | 0.56 | 1.05 | 0.5 | 0.47 | 0.73 |
Sale (Purchase) of Intangibles | - | - | - | -0.68 | -0.13 |
Investment in Securities | -1.2 | 2.64 | -9.98 | -0 | -0 |
Other Investing Activities | 65.26 | 35.89 | 3.22 | 0.18 | 10.93 |
Investing Cash Flow | 34.58 | -39.62 | -274.01 | -28.84 | -198.51 |
Short-Term Debt Issued | 217.96 | 40.78 | 59.18 | 133.67 | 24.31 |
Long-Term Debt Issued | 54.01 | 93.3 | 24.24 | - | 0.12 |
Total Debt Issued | 271.98 | 134.08 | 83.42 | 133.67 | 24.43 |
Short-Term Debt Repaid | -101.41 | -0.35 | -32.08 | -8.51 | -102.63 |
Long-Term Debt Repaid | -10.55 | -12.18 | - | -2.62 | - |
Total Debt Repaid | -111.97 | -12.53 | -32.08 | -11.13 | -102.63 |
Net Debt Issued (Repaid) | 160.01 | 121.55 | 51.34 | 122.54 | -78.2 |
Common Dividends Paid | -38.01 | -38.01 | -38.01 | -38.01 | -38.01 |
Other Financing Activities | -159.89 | -104.84 | -91.11 | -101.21 | -106.11 |
Financing Cash Flow | -37.88 | -21.3 | -77.78 | -16.68 | -222.32 |
Net Cash Flow | -129.04 | 114.9 | 394.15 | 338.15 | -250.36 |
Free Cash Flow | -155.78 | 96.61 | 478.18 | 354.85 | -39.56 |
Free Cash Flow Growth | - | -79.80% | 34.76% | - | - |
Free Cash Flow Margin | -3.50% | 2.65% | 14.37% | 11.77% | -1.42% |
Free Cash Flow Per Share | -7.85 | 5.08 | 25.16 | 18.67 | -2.08 |
Cash Interest Paid | 159.88 | 104.84 | 91.11 | 101.21 | 106.11 |
Cash Income Tax Paid | 9.28 | 10.84 | 3.4 | 9.22 | 28.77 |
Levered Free Cash Flow | -627.38 | 111.33 | 332.4 | 141.3 | 697.65 |
Unlevered Free Cash Flow | -527.64 | 173.2 | 386.33 | 201.14 | 760.93 |
Change in Working Capital | -691.7 | -349.53 | 230.95 | -98.13 | -189.27 |